Climb Bio (CLYM) Assets Average (2021 - 2026)

Climb Bio's Assets Average history runs 6 years deep, the most recent figure standing at $160.1 million for Q1 2026.

• Quarterly Assets Average fell 23.4% year-over-year to $160.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.1 million (down 23.4% YoY) and the FY2025 annual result came in at $192.5 million, up 17.48% from the prior year.
• Assets Average was $160.1 million for Q1 2026 at Climb Bio, down from $175.0 million in the prior quarter.
• Across five years, Assets Average topped out at $224.1 million in Q3 2024 and bottomed at $109.9 million in Q1 2024.
• A 5-year average of $160.6 million and a median of $160.1 million in 2026 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average retreated 23.73% — and 2024, when it jumped 96.85%.
• Climb Bio's Assets Average stood at $137.9 million in 2022, then declined by 19.09% to $111.6 million in 2023, then soared by 96.85% to $219.7 million in 2024, then declined by 20.33% to $175.0 million in 2025, then retreated by 8.55% to $160.1 million in 2026.
• Business Quant data shows CLYM's Assets Average at $160.1 million in Q1 2026, $175.0 million in Q4 2025, and $187.3 million in Q3 2025.